Categories Earnings, Health Care
Key highlights from Palatin Technologies (PTN) Q3 2020 earnings results
Palatin Technologies, Inc. (NYSE: PTN) reported a narrower loss in the third quarter of fiscal 2020 helped by lower operating expenses as well as higher other income. The bottom line came in line with the analysts’ expectations.
The company has implemented multiple measures in response to the COVID-19 pandemic to safeguard the health and well-being of employees while continuing to advance its programs. The company anticipates restarting enrollment of phase 2 clinical study of dry eye disease in June 2020 with the data readout is targeted for Q4 of calendar 2020.
Palatin now expects to start a phase 2 proof-of-concept clinical study with an oral formulation of PL8177 in ulcerative colitis patients in the first half of the calendar 2021, with data readout in the first half of the calendar 2022. The company continues its assessment and development work related to the treatment of patients with diabetic retinopathy, with an IND targeted for mid-calendar 2021.
The company now anticipates filing an IND and commencing clinical trials with PL8177 for non-infectious uveitis, for which FDA granted orphan drug designation, in the second half of the calendar 2021. Palatin continues to closely monitor AMAG’s process related to the divestiture of Vyleesi and AMAG’s obligations under the Vyleesi license agreement.
Take a look at our Health Care articles here
Most Popular
Richtech’s mission is to transform the service industry through collaborative robotic solutions: President
Richtech Robotics Inc. (NASDAQ: RR) is a leading provider of robotic solutions, developing, manufacturing, and deploying novel products needed for automation in the service industry. The company's solutions include delivery,
What to expect when Darden Restaurants reports Q1 results
Darden Restaurants, Inc. (NYSE: DRI) is scheduled to release its first-quarter report on September 19, with analysts forecasting a year-over-year increase in sales and profit. The market will be keeping a
Oracle (ORCL) sees continued strong revenue growth in FY25
Oracle Corporation (NYSE: ORCL) started the new fiscal year on a high note with stronger-than-expected first-quarter results, driving the stock higher soon after the announcement. The tech giant’s earnings and
